Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Daré Bioscience ( (DARE) ) is now available.
On July 9, 2025, Daré Bioscience reconvened its stockholder meeting initially held on June 12, 2025, which was adjourned due to a lack of quorum. During the meeting, four proposals were voted on, including the election of Class II directors, the ratification of Haskell & White LLP as the independent accounting firm for 2025, approval of executive compensation, and the 2022 Plan Amendment, all of which were passed by the stockholders.
The most recent analyst rating on (DARE) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.
Spark’s Take on DARE Stock
According to Spark, TipRanks’ AI Analyst, DARE is a Underperform.
Daré Bioscience’s overall stock score is predominantly influenced by its financial instability, as reflected in the financial performance score. The company faces serious financial distress with negative equity and high liabilities. While there is potential upside from strategic initiatives and possible technical rebounds due to oversold conditions, these are overshadowed by financial and regulatory challenges.
To see Spark’s full report on DARE stock, click here.
More about Daré Bioscience
Daré Bioscience operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative products in women’s health.
Average Trading Volume: 25,629
Technical Sentiment Signal: Strong Sell
Current Market Cap: $21.24M
For detailed information about DARE stock, go to TipRanks’ Stock Analysis page.